BridgeBio Pharma Inc

NASDAQ:BBIO   3:59:50 PM EDT
48.45
+1.45 (+3.08%)
Products

BridgeBio Pharma Announces First Publication Of Preclinical Data For Its Potentially Best-In-Class Shp2 Inhibitor Designed For Treatment Of Resistant Cancer

Published: 10/07/2021 13:12 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Announces First Publication of Preclinical Data for Its Potentially Best-in-class Shp2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models.
Bridgebio Pharma - Preclinical Findings Demonstrated Efficacy in Non-small Cell Lung Cancer Driven by Ras Or Other Mapk-pathway Activating Mutations.